Miraculins To Conduct 2nd Pivotal Study For P2V Prostate Cancer Test

WINNIPEG, MANITOBA -- Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, announces today that it will be conducting a 2nd pivotal pre-biopsy screen study for its urine based P2V(TM) prostate cancer diagnostic test. The study will focus on men who have been referred to a urologist and subsequently have been selected for a prostate biopsy, but will be restricted to men who have a PSA score of between 2.5ng/ml and 10 ng/ml with a normal DRE (digital rectal exam) result. The objective of the study will be to determine the effectiveness of the P2V(TM) test in reducing the number of unnecessary biopsies in this key group of patients by bei...